Medical therapy: Where are we now?

American Journal of Health-System Pharmacy

Volumn 63, Issue SUPPL. 4, 2006, Pages

  Resman Targoff, Beth H ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF PHARMACY   (United States)

Author keywords

Arthritis; Chondroprotective agents; Clinical studies; Combined therapy; Hydroxychloroquine; Leflunomide; Mechanism of action; Methodology; Methotrexate; Sulfasalazine; Toxicity

Indexed keywords

AMINOTRANSFERASE; AURANOFIN; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD SALT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; MALONONITRILAMIDE; METHOTREXATE; MINOCYCLINE; PENICILLAMINE; PREDNISONE; SALAZOSULFAPYRIDINE; TERIFLUNOMIDE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AGRANULOCYTOSIS; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; BLOOD DYSCRASIA; BONE MARROW SUPPRESSION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CORTICOSTEROID INDUCED OSTEOPOROSIS; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DYSPEPSIA; DYSPNEA; EYE TOXICITY; FATIGUE; FETUS WASTAGE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; INFLAMMATION; INTERSTITIAL PNEUMONIA; JOINT INJURY; LEUKOPENIA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FIBROSIS; MALAISE; NAUSEA; OLIGOSPERMIA; OPPORTUNISTIC INFECTION; PAIN ASSESSMENT; PANCYTOPENIA; PARESTHESIA; PRIORITY JOURNAL; PROGNOSIS; RASH; RHEUMATOID ARTHRITIS; RIGIDITY; STEVENS JOHNSON SYNDROME; STOMATITIS; SYMPTOMATOLOGY; TERATOGENICITY; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT RESPONSE; VOMITING;

EID: 33748797194     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060363     Document Type: Conference Paper

References (23)

1. Borchers AT, Keen CL, Cheema GS et al. The use of methotrexate in rheumatoid arthritis. Semin Arthritis Rheum. 2004; 34:465-83.
2. Rau R, Herborn G. Benefit and risk of methotrexate treatment in rheumatoid arthritis. Clin Exp Rheumatol. 2004; 22(suppl 35):S83-94.
3. Kremer JM. Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: followup after a mean of 13.3 years. Arthritis Rheum. 1997; 40:984-5.
4. Van Ede AE, Laan RF, Rood MJ et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2001; 44:1515-24.
5. Khanna D, Park GS, Paulus HE et al. Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies. Arthritis Rheum. 2005; 52:3030-8.
6. Case JP. Old and new drugs used in rheumatoid arthritis: a historical perspective: part 1: the older drugs. Am J Ther. 2001; 8:123-43.
7. Plosker GL, Croom KF. Sulfasalazine: a review of its use in the management of rheumatoid arthritis. Drugs. 2005; 65:1825-49.
8. Case JP. Old and new drugs used in rheumatoid arthritis: a historical perspective: part 2: the newer drugs and drug strategies. Am J Ther. 2001; 8:163-79.
9. Cush JJ. Safety overview of new disease-modifying antirheumatic drugs. Rheum Dis Clin North Am. 2004; 30:237-55.
10. Maddison P, Kiely P, Kirkham B et al. Leflunomide in rheumatoid arthritis: recommendations through a process of consensus. Rheumatology. 2005; 44:280-6.
11. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum. 2002; 46:328-46.
12. Marmor MF. Hydroxychloroquine at the recommended dose (≤6.5 mg/kg/day) is safe for the retina in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Rheumatol. 2004; 22:143-4.
13. Paulus HE. Defining remission in rheumatoid arthritis: what is it? Does it matter? J Rheumatol. 2004; 31:1-4.
14. Hider SL, Buckley C, Silman AJ et al. Factors influencing response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis. J Rheumatol. 2005; 32:11-6.
15. Smolen JS, Aletaha D, Keystone E. Superior efficacy of combination therapy for rheumatoid arthritis: fact or fiction? Arthritis Rheum. 2005; 52:2975-83.
16. O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med. 2004; 350:2591-2602.
17. Kremer J, Genovese M, Cannon GW et al. Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo-controlled trial. J Rheumatol. 2004; 31:1521-31.
18. Kalden JR, Smolen JS, Emery P et al. Leflunomide in combination therapy. J Rheumatol. 2004; 31(suppl 71):25-30.
19. O'Dell JR, Leff R, Paulsen G et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002; 46:1164-70.
20. Puolakka K, Kautiainen H, Möttönen T et al. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. Arthritis Rheum. 2004; 50:55-62.
21. Puolakka K, Kautiainen H, Möttönen T et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum. 2005; 52:36-41.
22. Grigor C, Capell H, Stirling A et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004; 364:263-9.
23. Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart C et al. Clinical and radiographie outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005; 52:3381-90.